Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty

V Oduncu, AC Tanalp, A Erkol, D Sırma… - The American journal of …, 2011 - Elsevier
V Oduncu, AC Tanalp, A Erkol, D Sırma, C Dündar, T Akgün, E Türkyılmaz, A Kılıçgedik…
The American journal of cardiology, 2011Elsevier
Statins have many favorable pleiotropic effects beyond their lipid-lowering properties. The
aim of this study was to evaluate the impact of long-term statin pretreatment on the level of
systemic inflammation and myocardial perfusion in patients with acute myocardial
infarctions. This was a retrospective study of 1,617 patients with acute ST-segment elevation
myocardial infarctions who underwent primary percutaneous coronary intervention< 12
hours after the onset of symptoms. Angiographic no-reflow was defined as postprocedural …
Statins have many favorable pleiotropic effects beyond their lipid-lowering properties. The aim of this study was to evaluate the impact of long-term statin pretreatment on the level of systemic inflammation and myocardial perfusion in patients with acute myocardial infarctions. This was a retrospective study of 1,617 patients with acute ST-segment elevation myocardial infarctions who underwent primary percutaneous coronary intervention <12 hours after the onset of symptoms. Angiographic no-reflow was defined as postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow grade ≤2. Long-term statin pretreatment was significantly less common in the no-reflow group (6.2% vs 21%, p <0.001). The serum lipid profiles of the groups were similar (p >0.05 for all parameters). Baseline C-reactive protein levels (10 ± 8.2 vs 15 ± 14 mg/L, p <0.001) and the frequency of angiographic no-reflow (3.9% vs 14%, p <0.001) were significantly lower, and myocardial blush grade 3 was more common (50% vs 40%, p = 0.006) in the statin pretreatment group (n = 306). Moreover, the frequency of complete ST-segment resolution (>70%) (70% vs 59%, p <0.001) and the left ventricular ejection fraction were higher (49 ± 7.5% vs 46 ± 8.3%, p <0.001) and peak creatine kinase-MB was lower (186 ± 134 vs 241 ± 187 IU/L, p <0.001) in the statin-treated group. In conclusion, long-term statin pretreatment is associated with lower C-reactive protein levels on admission and better myocardial perfusion after primary percutaneous coronary intervention, leading to lower enzymatic infarct area and a more preserved left ventricular ejection fraction. This is a group effect independent of lipid-lowering properties.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果